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Nephrogenic Systemic Fibrosis
Review of 370 Biopsy-Conﬁrmed Cases
Zhitong Zou, MD,* Hong Lei Zhang, MD,* Giles H. Roditi, MD,†
Tim Leiner, MD, PHD,‡ Walter Kucharczyk, MD,§ Martin R. Prince, MD, PHD*
ew York, New York; Glasgow, United Kingdom; Utrecht, the Netherlands;
nd Toronto, Ontario, Canada
Discovery of an association between gadolinium-based contrast agents (GBCAs) and nephrogenic sys-
temic fibrosis (NSF) has led to less use of GBCA-enhancedmagnetic resonance imaging in dialysis patients
and patients with severe renal failure at risk of NSF, and the virtual elimination of new cases of NSF. But
shifting patients with renal failure to alternative imagingmethodsmay subject patients to other risks (e.g.,
ionizing radiation or iodinated contrast). This review paper examines 370 NSF cases reported in 98 articles
to analyze NSF risk factors. Eliminating multiple risk factors by limiting GBCA dose to a maximum of 0.1
mmol/kg, dialyzing patients undergoing dialysis quickly followingGBCA administration, delayingGBCA in
acute renal failure until after renal function returns or dialysis is initiated, and avoiding nonionic linear
GBCA in patients with renal failure especially when there are proinflammatory conditions may substan-
tially reduce the risk of NSF. (J Am Coll Cardiol Img 2011;4:1206–16) © 2011 by the American College of
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is a fibrosing condition involving
skin, subcutaneous tissues, and
sometimes internal organs that oc-
urs only in patients with acute or severe
hronic renal insufficiency. Discovery of an
ssociation with gadolinium-based contrast
gents (GBCAs), especially at high doses (1),
as led to hypotheses that GBCA could
rigger this condition. Additional risk factors
nclude dialysis (2), edema (3), hyperphos-
phatemia (4), epoetin use (5), and proinflam-
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1207To better understand which patients with renal
disease can safely undergo GBCA injection with
minimal risk of NSF, we compiled data from 370
NSF cases detailed in 98 case reports of NSF and
case series in which data on individual patients
was available (1,6,11–106).
Clinical Features of NSF
NSF typically presents with skin thickening and
hardening, especially in the lower extremities.
The extent ranges from just a small patch of skin
to extensive areas of the body. To date, this
condition has universally spared the face. The
thickened skin, sometimes described as “peau
d’orange,” may acquire a cobblestone texture,
dimpling, or a woody aspect, which is often
accompanied by mild to moderate edema. The
lesions may encompass joints. Joint contractures
(n  115) or limited range of motion (n  23)
ere present in 138 of 190 patients for whom
hese data were available. Five additional patients
eportedly had “stiffness” without contractures.
his suggests that one-third of the patients had a
ild form of NSF without contractures or limited
ange of motion.
Scleral plaque or injection was noted in 20
atients; otherwise, there was no facial involvement
eported. Some of the imaging features reported
ncluded soft-tissue activity on bone scanning (n 
), skin thickening on mammography (n  4),
ermal calcification (n  9), and inflammatory
hanges on computed tomography (CT) scans (n 
4). In 16 patients, internal organ involvement was
escribed.
NSF and GBCAs
In 76 of 98 articles, history of GBCA administra-
tion was investigated by the authors. Supplemental
data were provided by the authors of 47 articles via
e-mail communication so that data on GBCA
exposure were available for 325 patients. In these
patients, 298 (92%) were noted to have had GBCA
injections prior to NSF symptom onset. The exis-
tence of NSF in patients without prior gadolinium
exposure is one reason why the relationship of
GBCA with NSF remains just an association, and
GBCAs are not considered to be the proven cause
of NSF. Gadolinium appears to be one of the dcomponents that trigger NSF, but it may not be an
exclusive or necessary component.
The time interval between GBCA injection and
NSF was available for 196 patients. On average,
NSF developed 96 days following GBCA, ranging
from the same day to approximately 3 years. When
intervals between GBCA exposure and symptom
onset 1 year were excluded (i.e., no relationship
for 9 patients with an interval 1 year), then the
mean interval between GBCA exposure and symp-
tom onset was 62 days. Data on the incidence of
NSF in patients with renal failure who were ex-
posed to GBCA are shown in Table 1. The wide
range of incidence from 0% to 18% suggests that
many variables affect NSF risk.
Age, Sex, and Race in Reported Cases of NSF
The distribution for 341 patients for which sex was
available was approximately equally
weighted between men (n  181) and
women (n  160). For 359 patients with
age reported, the mean age was 51 years
(range, 8 to 87 years) (Fig. 1). There
were no cases of NSF reported in neo-
nates or toddlers, even though babies
with immature kidneys and low GFR
commonly receive high doses of GBCA,
especially for imaging congenital heart
disease. One possible reason is that the
immune system at this age is not suffi-
ciently developed to overreact to GBCA.
Reports of NSF in the aged (e.g., 70
years of age) are relatively infrequent, even
though elderly patients have more severe
renal disease and more per capita GBCA-enhanced
MRIs. This potential discrepancy may be due to a
less active immune system and reduced collagen
synthesis in the elderly (107). Indeed, the oldest
reported patient with NSF was only 87 years, in
spite of many elderly older than 90 years with low
GFR receiving high doses of GBCA.
In 173 patients, race was reported, including
Caucasian (n  96), black (n  37), Hispanic (n 
7), Chinese (n  7), Malay (n  1), unspecified
sian (n 1), Indian (n 1), Vietnamese (n 2),
apanese (n  19), and Brazilian (n  2). As
xpected, the majority of patients were Caucasian,
eflecting a high use of GBCA-enhanced MRI in
orth America and Europe. Lower incidence of
SF in China in spite of a large population has
een attributed to rare use of double- and triple-
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1208Renal Function
All patients with NSF were reported to have renal
dysfunction, and numerous authors emphasized the
Figure 1. Incidence of NSF by Age
For 346 cases reported in the literature for which age is available, t
decade of age is shown in green bars. For comparison, the age dis
examinations with glomerular ﬁltration rate 30 ml/min at Columb
years is shown in pink bars. Note that the peak incidence of NSF o
age. The number of infants 1 year (mean age 4.2 months) receivi
is shown in a yellow bar with diagonal stripes. No NSF cases have
large number receiving high-dose GBCA. A dwindling incidence for
(glomerular ﬁltration rate 30 ml/ min) receiving high doses of GB
NSF in Patients With Renal Failure Exposed to GBCA
Patient Cohort No. of Patients With NSF Incidence, %
261 4 1.5
146 dialysis 6 0.28
(GFR 15*) 1 1.2
2 (GFR 15*) 18 18.0
1 dialysis 13 3.1
4 dialysis 12 2.9
5 dialysis 1 0.4
1 dialysis‡ 0 0
infected CRF 5 6.7
5 uninfected CRF 2 0.26
7 dialysis 6 1.6
(GFR) units: ml/min/1.73 m2. †Note that this report made a distinction between
dialysis at the time of gadolinium-based contrast agent (GBCA) administration
systemic ﬁbrosis [NSF] 0.4%) and patients who started hemodialysis 2 days
due to acutely deteriorating renal function (incidence of NSF 19%). ‡Dialysis
doteridol.are.highest risk of NSF for GFR 15 ml/min (i.e.,
chronic kidney disease stage 5 (109). In 353 pa-
tients, there was sufficient detail reported to deter-
mine whether the patient around the time of
developing NSF was on dialysis, including hemo-
dialysis (n  205), peritoneal dialysis (PD) (n 
7), both (n  13), continuous veno-venous hemo-
filtration (CVVH) (n 4), or unspecified (n 37).
Thus, 80% (296 of 370) of patients with NSF were
on dialysis, indicating that it is a major risk factor.
For 57 patients with NSF presumably not on
dialysis, GFR was reported to range from 0 (anuric)
to 40 ml/min, with a mean value of 15 ml/min. For
3 patients in whom estimated GFR was 30
ml/min, there was acute renal failure indicating that
the true GFR was actually lower. Another patient
with an estimated GFR greater than 30 ml/min had
the GFR measured 1 month before GBCA
injection.
Acute versus chronic renal failure. In 192 patients for
hom data allowed discrimination between acute
umber of patients with nephrogenic systemic ﬁbrosis in each
tion for patients undergoing high-dose magnetic resonance
ollege of Physicians and Surgeons, New York, New York, over 10
s at 51 to 60 years of age, with no cases in patients 8 years of
igh-dose gadolinium-based contrast agents (GBCAs) at Columbia
n reported in infants in spite of their immature kidneys and a
70 years, even though there are many more at-risk patients
n elderly patients, was also noted.he n
tribu
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Author (Ref. #)
Othersen (62)
Panda (113) 2,
Chen (69) 81
Rydahl (109) 10
Collidge (38) 42
Shabana (106) 41
Prince (1)† 26
Reilly (119) 14
Provenzale (125) 29
30
Heinz-Peer (96) 36
*Glomerular ﬁltration rate
patients on chronic hemo
(incidence of nephrogenic
after GBCA administration
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1209acute deterioration of chronic renal failure. In the
remaining 134 patients, there was sufficient detail to
determine that the renal failure was chronic and
stable. Acute renal failure has also been reported as
an NSF risk factor, with an odds ratio of 13.4 (50).
However, in these 58 patients with acutely deteri-
orating renal function at the time of GBCA admin-
istration, only 19 had contractions reported.
Follow-up available for the 37 patients with NSF in
acute renal failure showed that 2 had a complete
resolution of NSF (5%) and 17 showed improve-
ments (46%). This is consistent with the tendency
for NSF to improve, with restoration of renal
function that may occur when acute renal failure
resolves. Thus, although acute renal failure in-
creases NSF risk, the NSF clinical course may not
be as debilitating.
One article looked at the difference in NSF risk
with acute renal failure between injecting high-dose
GBCA while serum creatinine level was rising
(NSF incidence 19%) versus injecting after serum
creatinine level had peaked (no cases of NSF in 41
patients) or after regular hemodialysis was started
(no cases of NSF in 32 patients) (1). This suggests
that NSF risk can be substantially reduced in
patients with acute renal failure by either dialyzing
shortly after GBCA injection or by delaying
GBCA-enhanced MRI until after serum creatinine
level has peaked and the renal failure is beginning to
resolve.
Timely effective dialysis. Although 296 patients were
n dialysis at the time of developing NSF, several
actors may have reduced dialysis effectiveness in
atients who developed NSF. In a disproportion-
tely large number of cases, PD (n 37) or CVVH
(n  4) was used; these methods of dialysis are
known to be less effective at rapidly removing
GBCA compared with hemodialysis (110,111). In
49 patients, it was specifically reported that GBCA-
enhanced abdominal magnetic resonance angiogra-
phy (MRA) was performed, which can assess for
renal artery stenosis as the cause of renal failure
before initiation of dialysis. When dialysis is initi-
ated, the first sessions are lower intensity so that the
patient can acclimate to the stress of hemodialysis.
In addition, for patients awaiting initiation of dial-
ysis, the interval between GBCA exposure for
MRA and first dialysis may have been longer than
the 2-day interval between sessions for patients on
chronic dialysis. In an additional 7 patients,
GBCA-enhanced MRA was used in patients
undergoing chronic dialysis to evaluate dialysis
fistulae. Patients undergoing dialysis with mal-functioning fistulae may not undergo effective
dialysis either before or following their GBCA-
enhanced MRA.
For the 56 patients in whom the interval between
GBCA administration and dialysis could be deter-
mined, dialysis was performed the same day in 6
patients, 1 day later in 13 patients, 2 days later in 9
patients, and 3 days later in 28 patients. This
suggests that the overwhelming majority of patients
on dialysis with NSF may have had a delay between
GBCA and receiving dialysis, may have used PD or
CVVH, were just beginning dialysis, or may have
had poor-quality dialysis due to reduced fistula
function. For 7 of the patients dialyzed within 2
days of GBCA exposure, the authors specifically
noted that it was low-intensity dialysis, which could
not be expected to remove as much gadolinium as
standard hemodialysis (39,112,113). These data
support the hypothesis that a single prompt, high-
quality hemodialysis reduces NSF risk, perhaps on
the order of 20-fold.
Kidney transplantation. Seventy-nine of 370 patients
(21%) were noted to have a renal transplant around
the time of the GBCA injection. In 36 of these 79
patients (46%), there was history of failing/failed
renal transplant. Although it was not always possi-
ble to tell the reason for the MR examination, it
appears that in most of these cases, GBCA was
being injected for an MRA of the renal transplant
artery to determine if there was a correctable renal
transplant artery stenosis.
Liver disease. Although liver disease and liver
ransplantation have been singled out in regula-
ory warnings for extra caution, liver disease was
ctually noted in only 26 patients. Furthermore, a
eview by Mazhar et al. (114) showed that liver
isease conferred no additional NSF risk beyond
he risk related to the underlying renal dys-
unction.
GBCA Dose
Several dose-reporting errors were corrected in the
correspondence with authors. In the 248 cases for
which data on GBCA dose were available or could
be estimated from the exam type, 30 patients (12%)
appeared to have received a standard dose of GBCA
(0.1 mmol/kg) in the MRI exam most immediately
preceding development of NSF, and 218 patients
(88%) received greater than a standard dose, also
known as high dose. The mean total dose was
estimated to be 41 ml—assuming that 0.1
mmol/kg is 15 ml and that patients undergoing
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1210MRI had a standard dose, whereas patients un-
dergoing MRA or using GBCA to replace iodin-
ated contrast for angiography had a double dose.
One article reported no cases of NSF in 63,597
single-dose gadodiamide administrations (with-
out screening for renal function) but 15 cases of
NSF following 8,997 high-dose GBCA admin-
istrations (1). Similarly, Broome et al. (112)
described 12 cases of NSF in 210 patients under-
going dialysis receiving high-dose gadodiamide
but no cases of NSF in 94 patients undergoing
dialysis receiving single-dose gadodiamide. This
yielded an odds ratio of 12:1 for high-dose
GBCA causing NSF, indicating that the risk of
NSF can be reduced 12-fold simply by using a
standard dose of 0.1 mmol/kg. Additional data
on the increased NSF risk with higher doses of
GBCA from case-controlled studies (38,63,115)
are listed in Table 2.
Although limiting the dose of GBCA to a
standard dose of 0.1 mmol/kg reduced NSF risk by
at least an order of magnitude, there have been
reports of NSF developing after exams being re-
peated with a second injection due to nondiagnostic
results with a poorly timed or extravasated first
injection (1). Thus, it is also necessary that
GBCA-enhanced MRI be performed particularly
carefully in these patients so that diagnostic
images are obtained and the patient does not
require a repeat examination. Part of dose reduc-
tion includes having the best technologists and
nurses performing the examinations on the best
possible equipment for at-risk patients to mini-
Table 2. Effect of GBCA Dose on Risk of NSF in Case-Controlled
Author (Ref. #) No. of Controls No. of Patients With NSF G
Kallen (63) 14 13
Marckmann (115) 19 19
Collidge (38) 408 13
Abbreviations as in Table 1.
of NSF Risk With Gadodiamide (Nonionic) and
glumine (Ionic)
ear Patient Population
NSF Cases With
Gd:DTPA Gadodiamide
008 High dose; eGFR* 30† 0/87 12/411
008 Unscreened 4/135,347 32/82,260‡
008 Worldwide NSF reports 8 157
rular ﬁltration rate calculated from serum creatinine level, age, race, and sex.
m2. ‡The odds ratio was 13.2 times greater for the risk with gadodiamide
tate dimeglumine (Gd:DTPA).(1.mize the need for repeat injections. Moreover,
MRA exams in the past used a high dose to make
up for equipment limitations. With state of the
art equipment, MRA is now possible with stan-
dard doses or less (116). FDA approval of gado-
fosveset, a high-relaxivity blood pool contrast
agent, also allows diagnostic MRA with low
doses even on older equipment.
Type of GBCA
Only 62 articles indicated the most likely type of
GBCA to which 231 patients were exposed. One
issue was a failure to keep accurate patients records
concerning GBCA administration before discovery
of the NSF association with GBCA such that the
type of GBCA had to be inferred from purchasing
or formulary records. Another issue is related to
confusion about the GBCA names, which resulted
in errata in at least 1 article (117). We also were able
to make several corrections after author correspon-
dence. Yet another issue pointed out by many
authors was the uncertainty about patient exposures
outside of the authors’ institution.
When information on type of GBCA was pro-
vided, gadodiamide (n  182), gadopentetate
dimeglumine (n  26), gadoversetamide (n  5),
gadobutrol (n  3), and multiple agents (n  15)
ere described; however, the accuracy and com-
leteness of these data were sometimes questioned
1). The reports involving gadobutrol are contro-
ersial (118). The large number of cases with
onionic agents (gadodiamide and gadoverset-
mide) (Table 3), which tend to have lower in vitro
tability compared with the ionic (gadopentetate
imeglumine, gadoxetate, gadofosveset, and gado-
enate) and macrocyclic (gadoteridol, gadobutrol)
gents, has led to hypotheses that lower chelate
tability may contribute to greater NSF risk
119,120,121). However, this does not necessarily
ranslate into greater overall risk for the individual
atient because nonionic contrast agents tend to
ave fewer serious allergic-type adverse events
dies
Dose in Controls GBCA Dose in Patients With NSF p Value
ml 80 ml 0.01
4 mmol/kg 0.44 mmol/kg 0.05
ml (0.23 mmol/kg) 45 ml (0.39 mmol/kg) 0.008Stu
BCA
20
0.3
30Table 3. Comparison
Gadopentetate Dime
Author (Ref. #) Y
Prince (1) 2
Wertman (120) 2
Broome (121) 2
*eGFR  estimated glome
†GFR units: ml/min/1.73
compared with gadopente122,123) and fewer deaths (124).
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1211Type of MRI Exam
MRI exam type was reported for 192 patients,
including 98 (51%) undergoing MRA, which likely
reflects the common use of high doses for this exam
(Table 4). Abdominal MRI (n  36 [19%]), in-
cluding liver and MR cholangiopancreatography,
was the second most common exam type, which
also likely reflects the tendency to use high doses
for liver MRI before 2008. Interestingly, there
are only 3 cases of cardiac MRI reported to be
temporally correlated with developing NSF in
spite of the common use of double-dose GBCA
and high incidence of renal disease in cardiac
MRI patients.
Proinflammatory Events
For 147 patients, it was possible to determine if
there was a “proinflammatory event” at the time of
GBCA injection, including recent major surgery (n
1), acute thrombosis (n  58), infection (n  44),
myocardial infarction (n  2), antiphospholipid
syndrome (n  12), and active systemic lupus
erythematosus (n  15). Provenzale (125) noted
hat infection increased the risk of NSF in patients
ndergoing dialysis by 25-fold.
Epoetin
Epoetin is commonly given to patients with renal
failure to boost hematocrit. Because epoetin is
known to be proinflammatory, the possibility that it
represents a contributing risk factor has been sug-
gested by several authors (5,117). Epoetin acts
through stimulation of the bone marrow; how-
ever, this stimulation is not specific to red cell
creation. Other bone marrow cell production is
also enhanced, including circulating free fibro-
cytes, which are implicated in the pathogenesis of
NSF. In 82 patients for whom details on their
medications were described, 66 (80%) were re-
ported to be taking epoetin, including at least 7
patients on high doses.
Acidosis
Acidosis has been a suspected risk factor since the
initial report by Grobner (23) of 5 patients who all
had acidosis at the time of GBCA injection. In 43
patients, data on either blood gas results near the
time of GBCA administration or bicarbonate al-
lowed for an assessment of acidosis. Twenty-three
patients (53%) were noted to be acidotic. Thisacidosis is believed to be a risk factor for transmet-
allation because the extra positively charged protons
presenting at lower pH compete with gadolinium-
binding sites on the chelator, weakening the
strength of the gadolinium-chelate bond. Associa-
tion of acidosis with NSF has also been reported by
others (56,126).
Hyperphosphatemia
Elevated serum phosphorus is common in patients
with renal failure, and the mean serum phosphorus
was 6.8 mg/dl (2.3 mmol/l) (normal 2.5 to 4.5
mg/dl [0.8 to 1.5 mmol/l]) for the 86 patients for
whom data were available. Hyperphosphatemia
presumably increases the risk of phosphate binding
and precipitation of gadolinium when it is tran-
siently released from the chelator, thereby prevent-
ing reassociation of gadolinium with the chelator.
The experimental work of Frenzel et al. (4) has
shown that the conditional stability of the nonionic
linear GBCAs is further reduced with significantly
increased (100-fold) release of gadolinium in
plasma at pH 7.4 when 10 mmol/l phosphate was
added to mimic the “milieu intérieur” of the chronic
renal failure state. This resulted in a 75% increase in
gadolinium release during the experiment compared
with normal serum. The addition of phosphate in
the same experiment with ionic linear chelates
resulted in some increase in initial gadolinium
release rate, but overall release was not increased
over the 15 days of the study. There was no effect
for macrocyclic GBCAs, which had no measurable
release of gadolinium.
Table 4. Types of GBCA Enhanced Examination Preceding NSF
GBCA Exam Type No. of Patients
MRA 98
MRI abdomen 36
MRI head 14
X-ray angiogram 13
MRI extremities 8
MRI unspeciﬁed 7
MRI pelvis 6
MRI spine 5
Cardiac 3
MRI neck 2
MRA  magnetic resonance angiography; MRI  magnetic resonance
imaging; other abbreviations as in Table 1.
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1212Outcomes
Most of the information relating to the severity of
the disease was subjective. For 254 patients for
whom follow-up data were available, 55 experi-
enced different degrees of NSF symptom improve-
ment and cure was noted in 6 patients. Partial (n 
8) or complete (n  3) improvement following
restoration of renal function occurred in 11 cases.
One patient with NSF was reported to have sub-
stantial improvement after renal transplant and
again got worse after rejection (68). The clinical
course was stable in 65 patients. Death was noted in
71 patients but was attributed to NSF in only 3
cases. Other causes of death included cardiopulmo-
nary disease (n  20), infections (n  7), general
anesthesia (n  1), systemic lupus erythematosus
n 1), lymphoma (n 1), renal cell carcinoma (n 1),
myeloma (n  1), toxic megacolon (n  1), mesen-
teric ischemia (n  1), severe stroke (n  1),
multiorgan involvement (n 2), sudden death (n
), and unknown (n  30). In 26 patients, the
ymptoms were progressive, and the authors only
entioned “alive” without further details for an-
ther 31 patients.
Screening to Identify Patients at Risk
Because 80% of patients with NSF were on dialysis,
this is the most important risk factor for screening
to identify at-risk patients. Renal transplant wasPharmacother 2007;41:1481–5. options for the ithat this is another important risk factor. For all
inpatients, existing serum creatinine data should be
checked to identify patients with GFR lower than
30 ml/min. Serum creatinine level should also be
checked in outpatients when severe renal impair-
ment is discovered in the MR patient safety
questionnaire.
Discussion and Conclusion
The surveys conducted in this paper suggest that
many high-MR-volume institutions have had no
recent NSF cases (1). In addition, changes in
GBCA use since the association between NSF and
GBCA was reported in 2006 have virtually elimi-
nated new cases reported to the FDA (9), European
Medicines Agency, and manufacturers. The data
compiled in this review of 370 reported cases suggest
that reductions in risk may be attained with each of
the following: 1) avoiding high doses of GBCA (0.1
mmol/kg); 2) avoiding nonionic linear chelates in
patients undergoing dialysis and patients with GFR
30 ml/min, especially in the setting of proinflam-
matory conditions; 3) dialyzing quickly after GBCA
administration for patients already on dialysis; and 4)
avoiding GBCA in acute renal failure, especially while
serum creatinine level is rising.
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